Publications by authors named "D Atanackovic"

Background: Anti-CD19 CAR-T therapy has been a breakthrough in treatment of primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant previous second line of high dose chemotherapy and autologous stem cell transplantation (HDT/ASCT). However, in clinical practice, high risk patients with chemoimmunotherapy sensitive disease continue to receive salvage chemoimmunotherapy or cannot access CAR-T in a timely manner and thus may still proceed to HDT/ASCT. Little is known about clinical outcomes of CAR-T in patients who receive HDT/ASCT compared to those who are transplant-naïve.

View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2, responsible for COVID-19, has caused over 7 million deaths worldwide since its emergence, leading to trials of treatments like the anti-IL6 inhibitor tocilizumab, which failed to significantly improve survival rates.
  • Researchers isolated extracellular vesicles (EVs) from 39 severe COVID-19 patients to explore their potential as biomarkers, finding that specific viral proteins (spike and nucleocapsid) were dynamic in expression during treatment and recovery.
  • The study suggests that the changing levels of EV viral proteins could correlate with clinical outcomes, indicating that EVs might help identify long COVID and other complications in patients with severe cases.
View Article and Find Full Text PDF
Article Synopsis
  • Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for treating patients with multiple myeloma who have not responded to other treatments.
  • Out of 255 patients, 236 received the therapy, and many of them didn't qualify for earlier trials, but the results were still positive.
  • Most patients experienced some side effects, but many showed good responses to the treatment, with a significant percentage remaining cancer-free after one year.
View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy in cancer treatment. Still, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells.

View Article and Find Full Text PDF